Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 531 entries
Sorted by: Best Match Show Resources per page
Efficacy of tolvaptan in patients with refractory ascites in a clinical setting.

World journal of hepatology

Ohki T, Sato K, Yamada T, Yamagami M, Ito D, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K.
PMID: 26140088
World J Hepatol. 2015 Jun 28;7(12):1685-93. doi: 10.4254/wjh.v7.i12.1685.

AIM: To elucidate the efficacies of tolvaptan (TLV) as a treatment for refractory ascites compared with conventional treatment.METHODS: We retrospectively enrolled 120 refractory ascites patients between January 1, 2009 and September 31, 2014. Sixty patients were treated with oral...

Cite
Ohki T, Sato K, Yamada T, et al. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol. 2015;7(12):1685-93doi: 10.4254/wjh.v7.i12.1685.
Ohki, T., Sato, K., Yamada, T., Yamagami, M., Ito, D., Kawanishi, K., Kojima, K., Seki, M., Toda, N., & Tagawa, K. (2015). Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World journal of hepatology, 7(12), 1685-93. https://doi.org/10.4254/wjh.v7.i12.1685
Ohki, Takamasa, et al. "Efficacy of tolvaptan in patients with refractory ascites in a clinical setting." World journal of hepatology vol. 7,12 (2015): 1685-93. doi: https://doi.org/10.4254/wjh.v7.i12.1685
Ohki T, Sato K, Yamada T, Yamagami M, Ito D, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol. 2015 Jun 28;7(12):1685-93. doi: 10.4254/wjh.v7.i12.1685. PMID: 26140088; PMCID: PMC4483550.
Copy Download .nbib Format: NLM
Effect of aldosterone on epithelial-to-mesenchymal transition of human peritoneal mesothelial cells.

Kidney research and clinical practice

Yu M, Shin HS, Lee HK, Ryu DR, Kim SJ, Choi KB, Kang DH.
PMID: 26484027
Kidney Res Clin Pract. 2015 Jun;34(2):83-92. doi: 10.1016/j.krcp.2015.03.005. Epub 2015 Apr 25.

BACKGROUND: Peritoneal fibrosis is one of the major causes of technical failure in patients on peritoneal dialysis. Epithelial-to-mesenchymal transition (EMT) of the peritoneum is an early and reversible mechanism of peritoneal fibrosis. Human peritoneal mesothelial cells (HPMCs) have their...

Cite
Yu M, Shin HS, Lee HK, et al. Effect of aldosterone on epithelial-to-mesenchymal transition of human peritoneal mesothelial cells. Kidney Res Clin Pract. 2015;34(2):83-92doi: 10.1016/j.krcp.2015.03.005.
Yu, M., Shin, H. S., Lee, H. K., Ryu, D. R., Kim, S. J., Choi, K. B., & Kang, D. H. (2015). Effect of aldosterone on epithelial-to-mesenchymal transition of human peritoneal mesothelial cells. Kidney research and clinical practice, 34(2), 83-92. https://doi.org/10.1016/j.krcp.2015.03.005
Yu, Mina, et al. "Effect of aldosterone on epithelial-to-mesenchymal transition of human peritoneal mesothelial cells." Kidney research and clinical practice vol. 34,2 (2015): 83-92. doi: https://doi.org/10.1016/j.krcp.2015.03.005
Yu M, Shin HS, Lee HK, Ryu DR, Kim SJ, Choi KB, Kang DH. Effect of aldosterone on epithelial-to-mesenchymal transition of human peritoneal mesothelial cells. Kidney Res Clin Pract. 2015 Jun;34(2):83-92. doi: 10.1016/j.krcp.2015.03.005. Epub 2015 Apr 25. PMID: 26484027; PMCID: PMC4570652.
Copy Download .nbib Format: NLM
Spironolactone Treatment and Effect on Survival in Chronic Heart Failure Patients with Reduced Renal Function: A Propensity-Matched Study.

Cardiorenal medicine

Stubnova V, Os I, Grundtvig M, Atar D, Waldum-Grevbo B.
PMID: 28611786
Cardiorenal Med. 2017 Feb;7(2):128-136. doi: 10.1159/000454933. Epub 2017 Jan 20.

BACKGROUND/AIMS: Spironolactone may be hazardous in heart failure (HF) patients with renal dysfunction due to risk of hyperkalemia and worsened renal function. We aimed to evaluate the effect of spironolactone on all-cause mortality in HF outpatients with renal dysfunction...

Cite
Stubnova V, Os I, Grundtvig M, et al. Spironolactone Treatment and Effect on Survival in Chronic Heart Failure Patients with Reduced Renal Function: A Propensity-Matched Study. Cardiorenal Med. 2017;7(2):128-136doi: 10.1159/000454933.
Stubnova, V., Os, I., Grundtvig, M., Atar, D., & Waldum-Grevbo, B. (2017). Spironolactone Treatment and Effect on Survival in Chronic Heart Failure Patients with Reduced Renal Function: A Propensity-Matched Study. Cardiorenal medicine, 7(2), 128-136. https://doi.org/10.1159/000454933
Stubnova, Viera, et al. "Spironolactone Treatment and Effect on Survival in Chronic Heart Failure Patients with Reduced Renal Function: A Propensity-Matched Study." Cardiorenal medicine vol. 7,2 (2017): 128-136. doi: https://doi.org/10.1159/000454933
Stubnova V, Os I, Grundtvig M, Atar D, Waldum-Grevbo B. Spironolactone Treatment and Effect on Survival in Chronic Heart Failure Patients with Reduced Renal Function: A Propensity-Matched Study. Cardiorenal Med. 2017 Feb;7(2):128-136. doi: 10.1159/000454933. Epub 2017 Jan 20. PMID: 28611786; PMCID: PMC5465786.
Copy Download .nbib Format: NLM
The Effect of Tween 20, 60, and 80 on Dissolution Behavior of Sprionolactone in Solid Dispersions Prepared by PEG 6000.

Advanced pharmaceutical bulletin

Akbari J, Saeedi M, Morteza-Semnani K, Kelidari HR, Sadegh Moghanlou F, Zareh G, Rostamkalaei S.
PMID: 26504767
Adv Pharm Bull. 2015 Sep;5(3):435-41. doi: 10.15171/apb.2015.059. Epub 2015 Sep 19.

PURPOSE: Solid dispersions have been efficient in improving the dissolution rate and bioavailability of hydrophobic drugs. The aim of the present study was enhancement of the dissolution profile of Spironolactone using solid dispersion.METHODS: Spironolactone solid dispersions (1:1, 1:2 and...

Cite
Akbari J, Saeedi M, Morteza-Semnani K, et al. The Effect of Tween 20, 60, and 80 on Dissolution Behavior of Sprionolactone in Solid Dispersions Prepared by PEG 6000. Adv Pharm Bull. 2015;5(3):435-41doi: 10.15171/apb.2015.059.
Akbari, J., Saeedi, M., Morteza-Semnani, K., Kelidari, H. R., Sadegh Moghanlou, F., Zareh, G., & Rostamkalaei, S. (2015). The Effect of Tween 20, 60, and 80 on Dissolution Behavior of Sprionolactone in Solid Dispersions Prepared by PEG 6000. Advanced pharmaceutical bulletin, 5(3), 435-41. https://doi.org/10.15171/apb.2015.059
Akbari, Jafar, et al. "The Effect of Tween 20, 60, and 80 on Dissolution Behavior of Sprionolactone in Solid Dispersions Prepared by PEG 6000." Advanced pharmaceutical bulletin vol. 5,3 (2015): 435-41. doi: https://doi.org/10.15171/apb.2015.059
Akbari J, Saeedi M, Morteza-Semnani K, Kelidari HR, Sadegh Moghanlou F, Zareh G, Rostamkalaei S. The Effect of Tween 20, 60, and 80 on Dissolution Behavior of Sprionolactone in Solid Dispersions Prepared by PEG 6000. Adv Pharm Bull. 2015 Sep;5(3):435-41. doi: 10.15171/apb.2015.059. Epub 2015 Sep 19. PMID: 26504767; PMCID: PMC4616884.
Copy Download .nbib Format: NLM
Evolving role for mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction.

Current opinion in cardiology

Miller RJH, Howlett JG.
PMID: 25574896
Curr Opin Cardiol. 2015 Mar;30(2):168-172. doi: 10.1097/HCO.0000000000000147.

PURPOSE OF REVIEW: The majority of randomized clinical trials in heart failure with preserved ejection fraction (HFpEF) have failed to show meaningful improvements in clinical outcomes. Recent randomized trials have shown benefits from mineralocorticoid receptor antagonists (MRAs) in the...

Cite
Miller RJH, Howlett JG. Evolving role for mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction. Curr Opin Cardiol. 2015;30(2):168-172doi: 10.1097/HCO.0000000000000147.
Miller, R. J. H., & Howlett, J. G. (2015). Evolving role for mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction. Current opinion in cardiology, 30(2), 168-172. https://doi.org/10.1097/HCO.0000000000000147
Miller, Robert J H, and Howlett, Jonathan G. "Evolving role for mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction." Current opinion in cardiology vol. 30,2 (2015): 168-172. doi: https://doi.org/10.1097/HCO.0000000000000147
Miller RJH, Howlett JG. Evolving role for mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction. Curr Opin Cardiol. 2015 Mar;30(2):168-172. doi: 10.1097/HCO.0000000000000147. PMID: 25574896.
Copy Download .nbib Format: NLM
Mineralocorticoid receptors in the ventral hippocampus are involved in extinction memory in rats.

PsyCh journal

Xing X, Wang H, Liang J, Bai Y, Liu Z, Zheng X.
PMID: 26271938
Psych J. 2014 Sep;3(3):201-13. doi: 10.1002/pchj.58. Epub 2014 Jul 02.

Fear extinction decreases conditioned fear responses that normally occur when a conditioned stimulus (CS) is repeatedly presented in the absence of an aversive unconditioned stimulus (US), which is the behavioral basis of exposure therapy for posttraumatic stress disorder (PTSD)....

Cite
Xing X, Wang H, Liang J, et al. Mineralocorticoid receptors in the ventral hippocampus are involved in extinction memory in rats. Psych J. 2014;3(3):201-13doi: 10.1002/pchj.58.
Xing, X., Wang, H., Liang, J., Bai, Y., Liu, Z., & Zheng, X. (2014). Mineralocorticoid receptors in the ventral hippocampus are involved in extinction memory in rats. PsyCh journal, 3(3), 201-13. https://doi.org/10.1002/pchj.58
Xing, Xiaoli, et al. "Mineralocorticoid receptors in the ventral hippocampus are involved in extinction memory in rats." PsyCh journal vol. 3,3 (2014): 201-13. doi: https://doi.org/10.1002/pchj.58
Xing X, Wang H, Liang J, Bai Y, Liu Z, Zheng X. Mineralocorticoid receptors in the ventral hippocampus are involved in extinction memory in rats. Psych J. 2014 Sep;3(3):201-13. doi: 10.1002/pchj.58. Epub 2014 Jul 02. PMID: 26271938.
Copy Download .nbib Format: NLM
End-stage Liver Disease in Children.

Current treatment options in gastroenterology

Squires RH.
PMID: 11560788
Curr Treat Options Gastroenterol. 2001 Oct;4(5):409-421. doi: 10.1007/s11938-001-0006-6.

The treatment of children with end-stage liver disease involves the coordinated management of nutritional deficiencies, ascites, pruritus, encephalopathy, and portal hypertension. The implementation of management strategies depends upon a parent or guardian to administer the plan in the context...

Cite
Squires RH. End-stage Liver Disease in Children. Curr Treat Options Gastroenterol. 2001;4(5):409-421doi: 10.1007/s11938-001-0006-6.
Squires, R. H. (2001). End-stage Liver Disease in Children. Current treatment options in gastroenterology, 4(5), 409-421. https://doi.org/10.1007/s11938-001-0006-6
Squires, Robert H.. "End-stage Liver Disease in Children." Current treatment options in gastroenterology vol. 4,5 (2001): 409-421. doi: https://doi.org/10.1007/s11938-001-0006-6
Squires RH. End-stage Liver Disease in Children. Curr Treat Options Gastroenterol. 2001 Oct;4(5):409-421. doi: 10.1007/s11938-001-0006-6. PMID: 11560788.
Copy Download .nbib Format: NLM
Cytomegalovirus myocarditis in a healthy infant: Complete recovery after ganciclovir treatment.

Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies

Dehtiar N, Eherlichman M, Picard E, Kleid D, Glaser J, Raveh D, Schlesinger Y.
PMID: 12793954
Pediatr Crit Care Med. 2001 Jul;2(3):271-273. doi: 10.1097/00130478-200107000-00015.

OBJECTIVES: To report a case of acute myocarditis caused by cytomegalovirus infection in a 15-month-old immunocompetent infant completely recovered with ganciclovir treatment. DESIGN: Descriptive case report. SETTING: Pediatric intensive care unit in a general hospital. Patient: A 15-month-old healthy...

Cite
Dehtiar N, Eherlichman M, Picard E, et al. Cytomegalovirus myocarditis in a healthy infant: Complete recovery after ganciclovir treatment. Pediatr Crit Care Med. 2001;2(3):271-273doi: 10.1097/00130478-200107000-00015.
Dehtiar, N., Eherlichman, M., Picard, E., Kleid, D., Glaser, J., Raveh, D., & Schlesinger, Y. (2001). Cytomegalovirus myocarditis in a healthy infant: Complete recovery after ganciclovir treatment. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2(3), 271-273. https://doi.org/10.1097/00130478-200107000-00015
Dehtiar, Natalie, et al. "Cytomegalovirus myocarditis in a healthy infant: Complete recovery after ganciclovir treatment." Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies vol. 2,3 (2001): 271-273. doi: https://doi.org/10.1097/00130478-200107000-00015
Dehtiar N, Eherlichman M, Picard E, Kleid D, Glaser J, Raveh D, Schlesinger Y. Cytomegalovirus myocarditis in a healthy infant: Complete recovery after ganciclovir treatment. Pediatr Crit Care Med. 2001 Jul;2(3):271-273. doi: 10.1097/00130478-200107000-00015. PMID: 12793954.
Copy Download .nbib Format: NLM
Treating resistant hypertension with spironolactone.

Current hypertension reports

Berecek KH, Kimbrough D.
PMID: 18765091
Curr Hypertens Rep. 2008 Jun;10(3):211-2. doi: 10.1007/s11906-008-0039-5.

No abstract available.

Cite
Berecek KH, Kimbrough D. Treating resistant hypertension with spironolactone. Curr Hypertens Rep. 2008;10(3):211-2doi: 10.1007/s11906-008-0039-5.
Berecek, K. H., & Kimbrough, D. (2008). Treating resistant hypertension with spironolactone. Current hypertension reports, 10(3), 211-2. https://doi.org/10.1007/s11906-008-0039-5
Berecek, Kathleen H, and Kimbrough, Denise. "Treating resistant hypertension with spironolactone." Current hypertension reports vol. 10,3 (2008): 211-2. doi: https://doi.org/10.1007/s11906-008-0039-5
Berecek KH, Kimbrough D. Treating resistant hypertension with spironolactone. Curr Hypertens Rep. 2008 Jun;10(3):211-2. doi: 10.1007/s11906-008-0039-5. PMID: 18765091.
Copy Download .nbib Format: NLM
Combination of drospirenone and estradiol: a new hormone therapy in postmenopausal women.

Women's health (London, England)

Huber JC.
PMID: 19804015
Womens Health (Lond). 2007 Jul;3(4):409-15. doi: 10.2217/17455057.3.4.409.

The problems that arise in connection with the menopause have been treated for many years with various hormone-replacement therapy formulations. The spironolactone derivative drospirenone is a novel progestin that, in combination with estradiol, provides a new low-dose, continuous, combined...

Cite
Huber JC. Combination of drospirenone and estradiol: a new hormone therapy in postmenopausal women. Womens Health (Lond). 2007;3(4):409-15doi: 10.2217/17455057.3.4.409.
Huber, J. C. (2007). Combination of drospirenone and estradiol: a new hormone therapy in postmenopausal women. Women's health (London, England), 3(4), 409-15. https://doi.org/10.2217/17455057.3.4.409
Huber, Johannes C. "Combination of drospirenone and estradiol: a new hormone therapy in postmenopausal women." Women's health (London, England) vol. 3,4 (2007): 409-15. doi: https://doi.org/10.2217/17455057.3.4.409
Huber JC. Combination of drospirenone and estradiol: a new hormone therapy in postmenopausal women. Womens Health (Lond). 2007 Jul;3(4):409-15. doi: 10.2217/17455057.3.4.409. PMID: 19804015.
Copy Download .nbib Format: NLM
Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure.

Proceedings (Baylor University. Medical Center)

Craft J.
PMID: 16200104
Proc (Bayl Univ Med Cent). 2004 Apr;17(2):217-20. doi: 10.1080/08998280.2004.11927973.

Eplerenone is the second oral aldosterone antagonist available in the USA for the treatment of essential hypertension and heart failure. Treatment has been associated with reductions in blood pressure and improved survival (15% reduction in total mortality) for patients...

Cite
Craft J. Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure. Proc (Bayl Univ Med Cent). 2004;17(2):217-20doi: 10.1080/08998280.2004.11927973.
Craft, J. (2004). Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure. Proceedings (Baylor University. Medical Center), 17(2), 217-20. https://doi.org/10.1080/08998280.2004.11927973
Craft, Jennifer. "Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure." Proceedings (Baylor University. Medical Center) vol. 17,2 (2004): 217-20. doi: https://doi.org/10.1080/08998280.2004.11927973
Craft J. Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure. Proc (Bayl Univ Med Cent). 2004 Apr;17(2):217-20. doi: 10.1080/08998280.2004.11927973. PMID: 16200104; PMCID: PMC1200656.
Copy Download .nbib Format: NLM
Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis.

Nephron extra

Takagi N, Tanizawa T, Kon V, Fogo AB, Ichikawa I, Ma J.
PMID: 22479265
Nephron Extra. 2012 Jan;2(1):17-26. doi: 10.1159/000334961. Epub 2012 Jan 31.

BACKGROUND: We previously showed that angiotensin type 1 receptor (AT1) blocker (ARB) attenuates glomerular injury in Nphs1-hCD25 (NEP25) transgenic mice, a model of selective podocyte injury. However, subsequent studies in NEP25 mice with podocyte-specific deficiency of AT1 revealed that...

Cite
Takagi N, Tanizawa T, Kon V, et al. Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis. Nephron Extra. 2012;2(1):17-26doi: 10.1159/000334961.
Takagi, N., Tanizawa, T., Kon, V., Fogo, A. B., Ichikawa, I., & Ma, J. (2012). Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis. Nephron extra, 2(1), 17-26. https://doi.org/10.1159/000334961
Takagi, Nobuaki, et al. "Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis." Nephron extra vol. 2,1 (2012): 17-26. doi: https://doi.org/10.1159/000334961
Takagi N, Tanizawa T, Kon V, Fogo AB, Ichikawa I, Ma J. Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis. Nephron Extra. 2012 Jan;2(1):17-26. doi: 10.1159/000334961. Epub 2012 Jan 31. PMID: 22479265; PMCID: PMC3318935.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 531 entries